Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a diagnosis of plaque-type psoriasis at least 6 months~* Plaque-type psoriasis covering at least 10% of total body surface areas~* Psoriasis area-and-severity index score of 12 or greater~* Considered by treating dermatologist to be a candidate for phototherapy or systemic treatment of psoriasis~* Women of childbearing potential and all men must agree to use adequate birth control measures~* Have no history of latent or active tuberculosis~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis or drug-induced psoriasis~* Women who are pregnant or nursing, or men and women planning pregnancy while enrolled in the study~* Patients who have a history of chronic or recurrent infectious disease or who have or have had a serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months~* Patients who have or ever have had a nontuberculous mycobacterial infection or opportunistic infection~* Patients known to be infected with human immunodeficiency virus, hepatitis B, or hepatitis C~* Patients who have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease~* Have any known malignancy or have a history of malignancy within the previous 5 years (with the exception of basal cell carcinoma of the skin that has been treated with no evidence of recurrence)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Placebo) (Type: PLACEBO_COMPARATOR): Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
- Group II (Ustekinumab 45 mg) (Type: EXPERIMENTAL): Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
- Group III (Ustekinumab 90 mg) (Type: EXPERIMENTAL): Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
- Group IV (Type: EXPERIMENTAL): Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
- Group V (Type: EXPERIMENTAL): Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).